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Summary The effect of hydralazine on tumours appears to vary depending on tumour type. Blood flow and
radiation sensitivity decrease more in murine tumours than in human tumour xenografts. In this study a
comparison between various tumour types has been made using in vivo 3'P nuclear magnetic resonance
spectroscopy (NMRS) to follow the metabolic responses occurring after clamping or intravenous administra-
tion of hydralazine (5 mg kg-'). Large increases in the Pi/total phosphate ratio were found with the murine
sarcomas, KHT and RIF-1 implanted into C3H/He mice. However little or no effect was seen for the two
human xenografted tumours, HX118 and HT29 implanted in MFI nu/nu/Ola mice. An intermediate response
was observed for KHT tumours grown in nu/nu mice. All tumours showed a large response to clamping. The
anaesthetic Hypnorm/Hypnovel has a great influence on the response of the tumour metabolism to hydral-
azine appearing to both prolong and increase the changes induced. There is evidence to support the theory
that the changes in 31p spectra are related to the oxygen status of the tumours.
There is current interest in developing physiological methods
for manipulating the oxygen level of tumours (see collected
references in 'Chemical Modifiers of Cancer Treatment', ed.
Malaise, E.P., Guichard, M. & Siemann, D.W., 1988). These
include systemic treatment with various vaso-active drugs
which, by influencing blood flow in tumours, either increase
or decrease the level of tumour hypoxia. The drugs nico-
tinamide and flunarizine both increase radiosensitivity in
solid murine tumours, which is indicative of an increase in
oxygenation (Horsman et al., 1988; Wood & Hirst, 1988).
Conversely, several studies have shown that high doses of
hydralazine (>2.5 mg kg-') induce tumour hypoxia in a
variety of experimental tumours (Brown, 1987; Chaplin &
Acker, 1987; Stratford et al., 1987) and this leads to a
decrease in radiosensitivity. There is an advantage in selec-
tively increasing tumour hypoxia since oxygen deficiency per-
mits the direct activation of bioreductive drugs with potential
applications in both cancer therapy and diagnosis.
Hydralazine acts on the vasculature as a smooth muscle
relaxant and has been used clinically to reduce acute hyper-
tension. However, in most experimental murine tumours the
vasculature contains less or no smooth muscle and is there-
fore less susceptible to this vasodilatory action. Because of
this it is believed that hydralazine decreases blood flow in
these tumours by preferentially increasing the flow through
associated normal tissue. This so-called 'steal' effect (Jirtle,
1988) has been reported to occur in transplanted dog
tumours (Voorhees & Babbs, 1982) and in various experi-
mental tumours of murine origin (Chaplin, 1988; Chaplin &
Acker, 1987; Horsman et al., 1989; Guichard et al., 1991).
Preliminary clinical data appear conflicting. An initial
study of Acker et al. (1987) indicates that hydralazine
reduces blood flow in tumours of the head and neck region.
In contrast, Rowell et al. (1990) has shown that hydralazine
increases tumour blood flow in a large series of human lung
tumours where changes in blood flow were measured by a
radio-tracer technique. These differences may be due to the
dose dependent effect of hydralazine: Kalmus et al. (1990)
have shown that at low doses (0.5 mg kg-') hydralazine can
increase tumour blood flow. Since the evidence for induction
of enhanced tumour hypoxia comes almost entirely from
studies with transplantable murine tumours, there is a need
for studies utilising experimental tumours of human origin.
31P Nuclear magnetic resonance (NMR) spectroscopy has
been used to study metabolic changes in murine tumours
induced by hydralazine (Okunieff et al., 1988; Dunn et al.,
1989; Bhujwalla et al., 1990). In all these studies an increase
in the inorganic phosphate peak (Pi) was observed with a
corresponding decrease in the nucleoside triphosphate (NTP)
peaks. These changes have been attributed to enhanced anae-
robic metabolism arising from increased tumour hypoxia. In
one study (Dunn et al., 1989) it was also noted that the
spectra changes were greatly affected by the scheduling of the
anaesthetic used to sedate the mice during the experiments.
In the present study, 31P NMR spectroscopy has been used
to compare the effects of hydralazine in C3H mice bearing
murine tumours and mutant immune suppressed nu/nu mice
bearing transplanted human xenografted tumours. Murine
tumours were also implanted in the nu/nu mice, to determine
the effect of mouse host on the tumour response to hydra-
lazine.
Materials and methods
Tumour models
The KHT and RIF-I murine sarcoma lines were maintained
as described previously (Twentyman et al., 1980; Stratford et
al., 1988). Approximately 2 x 105 cells in 0.05 ml PBS were
implanted subcutaneously into the mid-dorsal pelvic region
of 8-12 week old C3H/He mice (category IV). KHT tumours
were also implanted into the same region of athymic nude
(MFI nu/nu/Ola) mice.
The HX118 human melanotic melanoma line was main-
tained as described by Cole et al. (1989) and implanted as
0.1 ml aliquots of tumour brei in nu/nu mice. The HT29
human colonic carcinoma was maintained by subcutaneous
implants for 1-2 mm tumour pieces into the flanks of the
nu/nu mice. For experimental purposes both xenograft
tumours were implanted into the mid-dorsal pelvic region.
Tumours were used for the NMR studies when they had
attained a volume of 300-400mm3. At least five animals
were used per experiment.
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Anaesthesia
Where appropriate, mice were injected intraperitoneally (ip)
with a 1:1:2 mixture of Hypnorm:Hypnovel:water* at a dose
of 0.2 ml per 25 g mouse. When necessary, further doses of
0.1 ml were administered in order to prolong anaesthesia.
Unanaesthetised mice were gently restrained in pvc jigs.
The mice were kept warm inside the magnet cavity, using
wax heating pads which maintained the body temperature at
about 37.5°C for up to 2 h.
Modification oftumour bloodflow
(a) Clamping: plastic D-shaped clamps were positioned at the
base of each tumour to totally occlude the blood supply for
periods up to 120 min.
(b) Hydralazine: doses of 5 mg kg-' were administered intra-
venously (iv) in phosphate buffered saline (PBS) at 5 LI g-
body weight.
NMR
The system consisted of a SISCO 200 spectrometer linked to
an Oxford Instruments 4.7T, 30 cm horizontal bore magnet.
A 2-turn, 7 mm diameter surface coil was used which fitted
the diameters of the tumours and allowed the measurement
of signals down to a depth of approximately 4mm. An
additional tune and match circuit was attached during shim-
ming to retune to the 'H resonance frequency. The ease of
shimming varied from mouse to mouse. The linewidth (full
width at half height) of the water signal was typically
50-60 Hz (0.25-0.30 p.p.m.). Occasionally, this could not be
reduced to less than 100 Hz, however, this did not appear to
be related either to the size or the haemorrhagic nature of the
tumour, even though the variability may be due to the
presence of paramagnetic iron complexes that can form in
haemorrhagic tissue. The quality of phosphorus spectra also
varied, but no obvious correlation was found with the final
linewidth of the water.
For the phosphorus spectra, 256 acquisitions were taken
with an interval of 2 s between scans. The pulse width corres-
ponded approximately to a 90 ffip angle at the centre of the
coil. Since typical T, relaxation times for phosphorus meta-
bolites at this field are around 1.5 s there is incomplete
relaxation between scans and the relative intensities of the
lines are therefore distorted in favour of lines with shorter T,
values, such as the ATP peaks. The data were multiplied by a
decaying exponential function in order to improve the signal-
to-noise ratio and give a line-broadening of 20 Hz. The
spectra were analysed by approximation to a set of Lorent-
zian-shaped lines on an irregular baseline. It was possible to
distinguish up to nine lines in the spectrum, which were
attributed to the P phosphate of NTP (P-NTP), diphosphodi-
esters (e.g. uridine-5-diphospho-glucose (UDPG)), nicotin-
amide adenine dinucleotide phosphate in the oxidised and
reduced forms (NADP/NADPH), a and y phosphates of
NTP (a-NTP and y-NTP), phosphocreatine (PCr), phosphodi-
ester (e.g. glycerylphosphocholine and glycerylphosphoethanol-
amine), inorganic phosphates (Pi) and phosphomonoesters
(phosphoethanolamine, phosphocholine and some sugar
phosphates (PME)). Frequently, a weak line beyond the
PME peak was also observed which may be assigned to
cyclic phosphates (Brown et al., 1987). ADP and phosphates
of other nucleotides also contributed to the lines assigned to
ATP.
Frequency shifts between Pi and PCr (when observable) or
NTP peaks were used to estimate pH (Robitaille et al., 1991).
Measurements from ox-NTP become particularly unreliable
during the course of experiments as the NTP peak intensities
decline. The errors were not less than 0.2 pH units.
In all cases, control spectra were taken before treatment.
The mice were then removed from the magnet, treated and
returned to the magnet for periods of up to 120min. Re-
shimming on the proton signal was carried out each time the
coil or the mouse were moved. For the studies beyond
120 min the animals were removed and kept warm for up to
3 h before being returned to the magnet.
Results
Spectral changes inducedby clamping
Figure 1 shows, for illustrative purposes, the changes in the
31P spectra occurring during clamping for the RIF-1 tumour
over a period of 120min. These changes can be charac-
terised, in all tumours, as an increase in the intensity of the
Pi peak, no change in the PME peak and a decrease in the
intensity of all other peaks. The PME/Pi ratio is consistently
higher in HX118 and HT29 xenografts tumours compared
with the murine tumours, RIF-I and KHT. For all tumour
types it was found that the peak area ratio Pi/total phosphate
was the most consistent method for expressing changes in the
phosphorus spectra. This is the ratio of the area of the fitted
Pi peak to the total area above the baseline.
Figure 2 shows, for all the tumours, the dependence of the
ratio Pi/total on the clamping time. With the exception ofthe
HX118 xenograft, all tumours, including KHT in nu/nu
mice, showed a maximum value of Pi/total after about
30 min clamping. The rise in the ratio for the melanoma is
slower. At the maximum values, Pi/total greater than 0.4, the
spectra contain just the two peaks corresponding to Pi and
PME (Figure lc).
The intracellular pH did not change significantly in the
KHT, RIF-l or HT29 tumours during clamping. The HXI 18
tumours did exhibit an apparent decline in pH by 40-60 min
post clamping (7.03 ± 0.24 to 6.62 ± 0.20, mean ± 1 s.d.).
c
Figure 1 a, Control spectra of RIF-I tumour showing peaks
corresponding to (1) phosphomonoesters, Pme; (2) inorganic
phosphates, Pi; (3) y-ATP; (4) a-ATP and (5) P-ATP. Changes in
these peaks are observed 20 min b, and 120 min c after clamping.
*Hypnovel: 1 ml contains 10 mg midazolam base as thehydrochloride.
Hypnorm: contains fentanyl citrate at 0.315 mgml- and fluanisome
at l0mgml '.
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Figure 2 Changes in the Pi/total phosphate ratios occurring
during 120 min of clamping for the murine tumours KHT (H)
and RIF-I (A) implanted in C3H mice and for the human
xenografted tumours HT29 (0) and HX118 (X) implanted in
nu/nu mice. V shows data obtained for the KHT murine tumour
implanted in nu/nu mice. Error bars indicate mean ±1 s.d.
Time after hydralazine administration (mins)
Figure 4 RIF-1 murine tumour in C3H mice. Legend as for
Figure 3.
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Effect ofhydralazine
Figure 3 shows the effect of hydralazine administration on
the Pi/total ratio in the KHT tumour. The range of values
for control and clamped tumours are indicated by the hatch-
ed regions in this and subsequent figures. In both anaes-
thetised and unanaesthetised mice treated with hydralazine,
the Pi/total ratios approach those for clamped tumours by
about 30 min post-treatment. The ratios in unanaesthetised
animals return to control values after about 5 h, whereas in
anaesthetised mice, the ratio remains at the value for
clamped tumours for at least 24 h, even though the mice have
apparently recovered from the anaesthetic at much earlier
times.
Figure 4 shows that the effect of hydralazine is much less
in the RIF-I tumour. In unanaesthetised mice the Pi/total
ratios increase significantly but do not reach the levels seen
with the KHT tumour. In anaesthetised mice, the effect of
hydralazine is both greater and prolonged. However, the
ratio at 24 h, although still different from the control, is
significantly less than that for clamping.
Figure 5 shows that hydralazine does not induce any
significant changes in the spectra of the two human xeno-
grafts, even when the mice are anaesthetised.
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Figure 3 Changes occurring in the Pi/total ratio for the KHT
tumour in C3H mice after the administration of hydralazine
(5 mg kg). Data are given for anaesthetised (0) and unanaes-
thetised (@) animals. The lower and upper hatched areas corre-
spond to control values and maximum clamped values obtained.
Error bars and hatched areas indicate the mean±+ s.d.
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Figure 5 Changes observed in the Pi/total ratio for anaesthetised
nu/nu mice bearing the human xenografted tumours HX118 (U)
and HT29 (@). The lower and upper hatched areas correspond
to the control values and maximum clamped values obtained for
the HX118 ( ) and HT29 ( m) respectively (mean± s.d).
The data for the KHT in anaesthetised nu/nu mice (Figure
6) indicate a small rise in Pi/total after hydralazine adminis-
tration, however this ratio does not attain the high value for
the same tumour implanted in C3H mice. The control growth
rate of the KHT tumour is very similar whether grown in
C3H or nu/nu mice, with the times to reach 4 x the initial
volume being 3.2 ± 0.4 and 3.6 ± 0.3 days respectively
(means ± s.e.). There was no significant change in intracel-
lular pH for any of the tumours after hydralazine.
Discussion
Severe changes in tumour blood flow should affect both the
supply of nutrients, including oxygen, and the removal of
waste products. An important question is whether the
changes in the 31P spectra in treated tumours are directly
attributable to the induction of hypoxia or are due rather to
the change in cell metabolism following the restriction of
nutrients generally.
Clamping reduces blood flow between the tumour and
normal tissue to almost zero (Denekamp et al., 1983).
Hydralazine substantially reduces blood flow in several
experimental murine tumours including the Lewis lung car-
cinoma (Chaplin, 1988), the SCCVII (Guichard et al., 1990),
the KHT (Honness & Bleehen, 1991) and the RIF-I tumours
(Horsman et al., 1989). In all cases the reported blood flow
was reduced to less than 25% of control values. Although
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Figure 6 Changes observed in the Pi/total ratio for anaesthetised
nu/nu mice bearing the murine KHT tumour. The lower and
upper hatched areas correspond to the control and maximum
clamped values obtained (mean±+ s.d.).
there is less evidence for the effect of this drug on human
tumour xenografts, Guichard et al. (1991) have shown that
hydralazine has less effect on the human tumours Nall and
HRTl1 grown in nu/nu mice, only reducing blood flow to
approximately 70% of the control value.
Reduction of tumour blood flow restricts the supply of
oxygen to the tumour cells thereby causing increased resis-
tance to x-irradiation. The time-scale over which the 31P
spectra change, following physical clamping of the tumour, is
significantly longer than the time required for the induction
ofradiobiological hypoxia. Complete radiobiological hypoxia
is seen for the KHT and RIF-l tumours after only 10min
clamping, whereas the maximum changes in Pi/total ratios
are not seen until after 30min of clamping. Furthermore,
the radiation resistance of the human xenografts tumours,
HX118, as measured by the growth delay assay, is increased
when irradiation is carried out during a 10min clamping
period (Cole et al., 1989). In contrast the NMR data show
that the maximum values ofthe Pi/total ratios for the HX1 18
tumour does not occur until 60 min post-clamping. An expla-
nation for this may be that the severity of hypoxia required
for the full induction of radiation resistance is insufficient for
the full expression of the metabolic changes indicated by the
31P NMR spectra. Also anaerobic glycolysis could augment
the ATP supply and delay the observed response. Anaerobic
glycolysis is likely to be accompanied by an acidification; this
could explain the prolonged time required by the HX118 to
achieve maximum changes in the spectra after clamping com-
pared to the other tumours.
The only tumour models in this study significantly affected
by hydralazine are the KHT and RIF-1 tumours where the
Pi/total ratios are significantly higher than the control values
30 min after drug administration. Complete radiobiological
hypoxia is also induced within 30 min of hydralazine (Strat-
ford et al., 1988; Dunn et al., 1989). Okunieff et al. (1988)
have reported similar changes in the 31p spectra after intra-
peritoneal administration of hydralazine for the FSaII
tumour implanted in the hind foot dorsum with a similar
relationship to the observed radioresistance induced in this
tumour. However, they observed the maximum effect 5 mn
after hydralazine, which was maintained for 60 min and
returned to normal after 90min. This difference in the time-
course may be due to the different tumour types, the sites of
implantation and the different routes of hydralazine adminis-
tration.
Cole et al. (1989) have shown, using the growth delay
assay, that although the HX118 human tumour xenograft
becomes significantly more radiation resistant after hydra-
lazine administration, this increased resistance is less than
that caused by 10 min clamping. This suggests that the effect
ofhydralazine on this tumour is less than that for the murine
tumours. Guichard et al. (1991) have also shown that hydra-
lazine has little effect on the radioresistance of some other
human xenografts. There is no effect on metabolism as seen
with 31P spectroscopy for either of the human xenografts
used in this study.
For KHT tumours grown in nu/nu mice the effect of
clamping on the 31P spectra is similar to that for the same
tumour grown in C3H mice. However, the effect of mouse
host becomes apparent following hydralazine administration
where there are much greater changes observed for the KHT
tumour implanted in C3H mice. This cannot be explained by
differences in the tumour growth rate and should be investi-
gated further. Guichard et al. (1991) also observed a similar
phenomenon between SCCVII tumours implanted in the
C3H and nu/nu mice.
The presence of the anaesthetic hypnorm/hypnovel can
both increase the magnitude and the duration of the changes
in 31p spectra. Although the control values do not seem to be
affected, Burney and Field have found that hypnorm/hyp-
novel does cause a reduction in blood pressure (personal
communication). Since hydralazine can also reduce blood
pressure in experimental mice (Okunieff et al., 1988) large
changes in blood pressure within the tumour could result
when hydralazine is administered in conjunction with hyp-
norm/hypnovel.
In conclusion, the effect of hydralazine on tumours is
clearly related to tumour type, the animal host and the
presence of anaesthetic. Although it is not yet possible to
categorically state that the changes in 31P spectra are directly
due to the oxygen status ofthe tumour, it is likely that this is
a major factor determining the relative concentrations of
phosphorus metabolites in experimental tumours. Previous
studies have shown that the mean P02 values of tumours
decrease with increasing size, a change which is coincident
with decreasing values of the NTP/Pi ratio (Vaupel et al.,
1989; Mueller-Klieser et al., 1990). Evelhoch et al. (1986) also
demonstrated a relationship between the distribution ofcellu-
lar environments with the RIF-I tumour using 02 perfusion
measurements and the tumour metabolic state as reflected in
the 31P NMR spectra. These observations suggest that clamp-
ing greatly reduces the oxygen status of all the tumour types
in this study, but any reduction caused by hydralazine is
insufficient for detection by 31P spectroscopy except in the
RIF-I and KHT murine tumours.
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